American Century Companies Inc. Has $22.08 Million Stake in GSK plc (NYSE:GSK)

American Century Companies Inc. grew its holdings in GSK plc (NYSE:GSK) by 9.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 652,865 shares of the pharmaceutical company’s stock after purchasing an additional 58,056 shares during the quarter. American Century Companies Inc.’s holdings in GSK were worth $22,080,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the business. Indiana Trust & Investment Management Co boosted its holdings in GSK by 200.0% in the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock valued at $25,000 after purchasing an additional 500 shares during the period. Crews Bank & Trust acquired a new position in shares of GSK during the fourth quarter valued at about $26,000. ST Germain D J Co. Inc. lifted its stake in shares of GSK by 195.5% in the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 522 shares during the period. Sunbelt Securities Inc. grew its position in GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after buying an additional 302 shares in the last quarter. Finally, Sierra Ocean LLC bought a new position in GSK during the fourth quarter valued at about $32,000. 15.74% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Morgan Stanley started coverage on GSK in a report on Wednesday, February 12th. They set an “equal weight” rating on the stock. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Seven equities research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat.com, GSK presently has a consensus rating of “Moderate Buy” and an average target price of $43.25.

GSK Stock Performance

Shares of NYSE:GSK opened at $38.74 on Monday. The stock has a market capitalization of $80.19 billion, a price-to-earnings ratio of 24.37, a price-to-earnings-growth ratio of 1.12 and a beta of 0.58. The business’s fifty day moving average price is $37.22 and its two-hundred day moving average price is $36.69. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.93. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. As a group, analysts predict that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be issued a $0.3932 dividend. This is an increase from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 annualized dividend and a dividend yield of 4.06%. The ex-dividend date is Friday, February 21st. GSK’s payout ratio is presently 98.74%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.